TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06261398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BETTER: motivational interviewing and text messaging
Description: Motivational interviewing to encourage individuals to address their social needs and engage with text messages that allow individuals to connect to their care team, a local organization that can help them address their social needs, and/or a resource that enables them to find help to address their needs based on their zip code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: No motivational interviewing or text messages will be provided.
Study: NCT05020873

Intervention type: OTHER
Intervention: Crizanlizumab
Description: Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06466226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple central venous lines in two sites separately
Description: Patients with two central venous lines in two sites separately (two central venous sites).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple central venous lines in one site (internal jugular vein)
Description: Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).
Study: NCT06005870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus RCHOP
Description: Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21
Study: NCT06290375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 tablet
Description: once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once-daily
Study: NCT06171321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1(Intravenous combined with oral)
Description: Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
Study: NCT06306521

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BeginNGS Test
Description: Genomic sequencing that screens for over 400 genetic diseases.
Study: NCT05932940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gonioscopy-Assisted Transluminal Trabeculotomy
Description: Ab interno angle surgery one of MIGS to lower IOP
Study: NCT06337071

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Description: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACYW135 Meningococcal Polysaccharide Vaccine
Description: ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
Study: NCT05521230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: Application of mouthwashes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cymenol mouthwash
Description: Application of mouthwashes
Study: NCT05234606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6290
Description: Escalating doses by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6290
Description: Escalating doses by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6290
Description: Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6290
Description: Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg via intravenous (IV) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg via intravenous (IV) injection in 21-day cycles
Study: NCT06407167

Intervention type: DIAGNOSTIC_TEST
Intervention: DN4 (Douleur Neuropathique 4 Questions) questionnaire
Description: DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination

Intervention type: DIAGNOSTIC_TEST
Intervention: DN4 (Douleur Neuropathique 4 Questions) questionnaire
Description: DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination
Study: NCT05182775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal bacteria transplantation
Description: Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
Study: NCT06365203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Through knee amputation
Description: Amputation Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Through knee amputation
Description: Amputation Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Above knee Amputation
Description: Amputation Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Above knee Amputation
Description: Amputation Technique
Study: NCT04906980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802
Description: JNJ-64281802 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (PEG400) will be administered orally.
Study: NCT05270590

Intervention type: PROCEDURE
Intervention: minimally invasive rheumatic mitral valve surgery
Description: First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start

Intervention type: PROCEDURE
Intervention: minimally invasive rheumatic mitral valve surgery
Description: First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
Study: NCT04360070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Parenteral General Anesthetic
Study: NCT06084520

Intervention type: DIAGNOSTIC_TEST
Intervention: Current Opioid Misuse Measure (COMM)-SWE
Description: Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral fluid drug test
Description: Oral fluid sampling to detect drugs. Analysis with LC-HRMS

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral fluid drug test
Description: Oral fluid sampling to detect drugs. Analysis with LC-HRMS

Intervention type: DIAGNOSTIC_TEST
Intervention: PETh
Description: Alcohol use detection

Intervention type: DIAGNOSTIC_TEST
Intervention: PETh
Description: Alcohol use detection

Intervention type: DIAGNOSTIC_TEST
Intervention: ASI-SR
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: AUDIT
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: DUDIT
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory - BPI
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient Global Impression of Change PGIC
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: GAD-7
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient Health questionnaire (PHQ9)
Description: Cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: DBS - cannabis test
Description: cross-validation form

Intervention type: DIAGNOSTIC_TEST
Intervention: DBS - cannabis test
Description: cross-validation form

Intervention type: OTHER
Intervention: Sample of Blood for later DNA and immunological analysis in future studies
Description: sample collection for future studies

Intervention type: OTHER
Intervention: Sample of Blood for later DNA and immunological analysis in future studies
Description: sample collection for future studies
Study: NCT05513989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified Magill forceps
Description: modified pediatric Magill forceps was used to assist nasotracheal intubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magill forceps
Description: Magill forceps was used to assist nasotracheal intubation.
Study: NCT00012779

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Program
Study: NCT05671432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04821466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset to provide a Virtual Reality Experience
Description: Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
Study: NCT05277545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology addiction education
Description: Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology addiction education
Description: Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
Study: NCT05171257

Intervention type: DRUG
Intervention: IV antibiotic treatment from prior
Description: patients receiving same IV antibiotic treatment from prior

Intervention type: DRUG
Intervention: differing IV antibiotic treatment
Description: patients receiving differing IV antibiotics from prior
Study: NCT05447468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength of lower trapezius
Description: Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength of middle trapezius
Description: Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength of serratus anterior
Description: Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed ultrasound
Description: With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Description: With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching of extensor carpi radialis brevis muscle
Description: Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching of extensor carpi radialis brevis muscle
Description: Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercises of wrist extensors
Description: Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises of wrist extensors
Description: Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
Study: NCT05548621

Intervention type: OTHER
Intervention: Decision aid
Description: Online interactive decision aid for RCC
Study: NCT06060964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathe Easier Progressive Web Application
Description: The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
Study: NCT05041751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Point Injection
Description: Receive trigger point injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Perform myofascial release

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06402708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: IMRT, 50Gy/25f
Study: NCT05335460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d1,Q3W
Study: NCT05260619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
Study: NCT04855526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/No CBD Marihuana
Description: high THC (65 mg THC) and no CBD (0 mg CBD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/High CBD Marihuana
Description: high THC (65 mg THC) and high CBD (50 mg CBD)
Study: NCT05957666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Oral Tablet
Description: oral misoprostol 50 microgram repeated after 6 hours if required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: vaginal misoprostol 50 microgram repeated after 6 hours if required
Study: NCT06115772

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05180942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium 40Mg Tab
Description: One tablet daily
Study: NCT04750642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI632D
Description: CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CI632
Description: CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
Study: NCT04234906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procainamide
Description: IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
Study: NCT04855526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No THC/No CBD Marihuana
Description: no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
Study: NCT05603702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
Study: NCT05565625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen A
Description: Participants will topically apply Sunscreen A at Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen B
Description: Participants will apply Sunscreen B at Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C
Description: Participants will apply Sunscreen C at Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen D
Description: Participants will apply Sunscreen D at Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen E
Description: Participants will apply Sunscreen E at Visit 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen F
Description: Participants will apply Sunscreen F at Visit 1.
Study: NCT06001203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet